Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.41 |
| ▸ | CA2 | P00918 | 6/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | CA6 | P23280 | 3/20 | 0.41 |
| ▸ | CA5A | P35218 | 3/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.40 |
| ▸ | FEN1 | P39748 | 5/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29512307 | 1.00 | CA1 (0.41) | CA1CA2CA9CA6CA5A | |
| SCHEMBL14058259 | 0.84 | — | — | |
| SCHEMBL10899533 | 0.83 | PGAM1 (0.35) | CYP2C9 | |
| SCHEMBL14058255 | 0.81 | — | — | |
| SCHEMBL6421776 | 0.76 | ALOX5AP (0.41) | CA1CA2CA9CA6CA5A | |
| SCHEMBL1080972 | 0.74 | CA2 (0.61) | CA1CA2CA9CA6CA5A | |
| Sulfamide SCHEMBL5230684 | 0.73 | CYP1A2 (0.44) | CA1CA2CA9CA6CA5A | |
| SCHEMBL8347239 | 0.72 | CA2 (0.58) | CA1CA2CA9CA6CA5A | |
| SCHEMBL4098897 | 0.72 | IDO1 (0.53) | — | |
| SCHEMBL206363 | 0.72 | IDO1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1456179-A1 | DEUTERATED SUBSTITUTED PYRAZOLYLBENZYLSULFONAMIDES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | Turicum Drug Development AG (CH) | 2004-09-15 | — | — | EP | claimed |
| WO-2003050091-A1 | DEUTERATED SUBSTITUTED PYRAZOLYLBENZYLSULFONAMIDES AND MEDICAMENTS COMPRISING SAID COMPOUNDS | TURICUM DRUG DEVELOPMENT AG (CH) | 2003-06-19 | — | — | WO | claimed |
| US-RE44048-E1 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder | G.D. SEARLE LLC (US) | 2013-03-05 | — | — | US | disclosed |
| US-8362062-B2 | Pharmaceutical compositions with improved dissolution | MCNEIL-PPC, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2339328-A2 | Pharmaceutical co-crystal compositions of celecoxib | Transform Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| EP-2054420-B1 | BENZIMIDAZO[1,2-C][1,2,3]THIADIAZOL-7-SULFONAMIDES AS INHIBITORS OF CARBONIC ANHYDRASE AND THE INTERMEDIATES FOR PRODUCTION THEREOF | BIOTECHNOLOGIJOS INST (LT) | 2011-06-22 | — | — | EP | disclosed |
| EP-2054420-A1 | BENZIMIDAZOÝ1,2-C¨Ý1,2,3¨THIADIAZOL-7-SULFONAMIDES AS INHIBITORS OF CARBONIC ANHYDRASE AND THE INTERMEDIATES FOR PRODUCTION THEREOF | Biotechnologijos Institutas (LT) | 2009-05-06 | — | — | EP | disclosed |
| US-20080293679-A1 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors | CARDAX PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| EP-1890729-A2 | USE OF CAROTENOIDS AND/OR CAROTENOID DERIVATIVES/ANALOGS FOR REDUCTION/INHIBITION OF CERTAIN NEGATIVE EFFECTS OF COX INHIBITORS | Cardax Pharmaceuticals, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2008016288-A1 | BENZIMIDAZO[1,2-C][1,2,3]THIADIAZOL-7-SULFONAMIDES AS INHIBITORS OF CARBONIC ANHYDRASE AND THE INTERMEDIATES FOR PRODUCTION THEREOF | BIOTECHNOLOGIJOS INSTITUTAS (LT) | 2008-02-07 | — | — | WO | disclosed |
| WO-2007129169-A2 | COX- II INHIBITORS FOR IMPROVING REPRODUCTIVE SUCCESS IN A FEMALE ANIMAL | PFIZER LIMITED (GB) | 2007-11-15 | — | — | WO | disclosed |
| US-5563165-A | PROSTAGLANDIN INHIBITOR; FDA ORANGE BOOK LISTED PATENT FOR CELEBREX | G. D. SEARL & CO. (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5521207-A | Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation | G.D. SEARLE & CO. (US) | 1996-05-28 | — | — | US | disclosed |
| US-5516907-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1996-05-14 | — | — | US | disclosed |
| US-5510496-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5508426-A | ANTIARTHRITIC AGENT | G. D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5504215-A | Substituted pyrazolyl benzenesulfonamide compounds for the treatment of inflammation | G. D. SEARLE & CO. (US) | 1996-04-02 | — | — | US | disclosed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293679-A1 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors | LPL, ALOX12, LCLAT1 | CA1 4043/4885CA2 2927/4885CA9 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.